Back to results
US 2010/0136558 A1Published application
Canine cd20 gene
AssigneeNihon University
InventorsRui KANO, Atsuhiko HASEGAWA, Chika INOUE
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeNihon University
InventorsRui KANO, Atsuhiko HASEGAWA, Chika INOUE
Estimating the term…
It is intended to clarify the CD20 amino acid sequence and its gene sequence which are essentially required in constructing an anti-CD20 antibody useful in treating animal malignant lymphoma. It is also intended to provide a method of diagnosing canine malignant lymphoma by using the CD20 gene sequence. Using monocytes in canine blood as a sample, mRNA is obtained and the full base sequence of canine CD20 gene (SEQ ID NO:2) is determined. Based on this sequence, its amino acid sequence (SEQ ID NO:1) is determined. Comparing the homologies with human and mouse CD20 genes and amino acid sequences, it is identified as canine CD20 gene. Moreover, a primer specific to the canine CD20 gene is constructed and the expression of the CD20 gene in a sample is examined, thereby giving a method of diagnosing canine B lymphocyte-origin malignant lymphoma.
An RNA encoding canine CD20 according to SEQ ID NO:
A polynucleotide having a homology of 70% or higher with an RNA sequence according to SEQ ID NO:
A polynucleotide having a homology of 80% or higher with an RNA sequence according to SEQ ID NO:
A primer according to SEQ ID NO:
A primer according to SEQ ID NO:
A DNA encoding canine CD20 according to SEQ ID NO:
A polynucleotide having a homology of 70% or higher with a DNA sequence according to SEQ ID NO:
A polynucleotide having a homology of 80% or higher with a DNA sequence according to SEQ ID NO:
Dependencies are inferred from the claim text.